D. E. Shaw & Co., Inc. Adicet Bio, Inc. Call Options Transaction History
D. E. Shaw & Co., Inc.
- $107 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ACET
# of Institutions
72Shares Held
59.2MCall Options Held
4.2KPut Options Held
6.7K-
Orbimed Advisors LLC San Diego, CA11.4MShares$11 Million0.39% of portfolio
-
Tang Capital Management LLC San Diego, CA8.22MShares$7.89 Million1.01% of portfolio
-
Ra Capital Management, L.P. Boston, MA7.54MShares$7.24 Million0.15% of portfolio
-
Goldman Sachs Group Inc New York, NY3.76MShares$3.61 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.21MShares$3.08 Million0.0% of portfolio
About Adicet Bio, Inc.
- Ticker ACET
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,030,800
- Market Cap $38.4M
- Description
- Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune respo...